Private equity firm Advent to sell generic drugmaker Zentiva to GTCR (updated)

Zentiva as

11/09/2025 14:51

Adds deal value from source in paragraph 2, background on Zentiva and previous deal reports from paragraph 4 onwards

Sept 11 (Reuters) - Czech generic drugmaker Zentiva 1SKF401E.BV said on Thursday that private equity group Advent International had agreed to sell the company to rival GTCR for an undisclosed value.

The deal values the Prague-based company at slightly more than 4 billion euros ($4.69 billion) including debt, according to a source with knowledge of the deal.

The Financial Times had first reported the deal on Wednesday, saying it was worth 4.1 billion euros.

Zentiva was acquired by Advent from French pharmaceutical giant Sanofi SASY.PA in 2018 for an enterprise value of 1.9 billion euros.

There have been reports of Advent mulling a sale of the generics drugmaker since 2021, with companies such as Polish drugmaker Polpharma and India's
Aurobindo Pharma
 ARBN.NS reported to be joining the race.

Zentiva supplies a wide range of generic and over-the-counter drugs such as paracetamol and co-codamol to more than 100 million people across Europe.

($1 = 0.8530 euros)

 (Reporting by Unnamalai L in Bengaluru and Andres Gonzalez Estebaran; Editing by Maju Samuel)

 ((Unnamalai.L@thomsonreuters.com;))